Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCieloPCLOF +6.74% 3-Year FCF Growth Rate is 29.70% as of Mar. 2026, which is 31% below its 10-year median of 43.10. The stock has 3 warning signs investors should review. Among 660 Drug Manufacturers companies, PharmaCielo ranks better than 72.12% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 29.70% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 43.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of PharmaCielo was 56.50% per year. The lowest was 29.70% per year. And the median was 43.10% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
PharmaCielo 3-Year FCF Growth Rate Related Terms
PCLOF vs ZTS: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where PharmaCielo's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 29.70% mean?
PharmaCielo (PCLOF) has a 3-Year FCF Growth Rate of 29.70% as of Mar. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for PharmaCielo and its competitors. This is 31% below median its historical median of 43.10. Over the past decade, PharmaCielo's 3-Year FCF Growth Rate has ranged from 29.70 to 56.50. According to the industry distribution chart, PharmaCielo ranks #184 out of 660 companies in the Drug Manufacturers industry, placing it in the top 27.9%.
Is PharmaCielo's 3-Year FCF Growth Rate too high?
PharmaCielo's current 3-Year FCF Growth Rate of 29.70% is 31% below median its 10-year median of 43.10. Over the past 10 years, this metric has ranged from a low of 29.70 to a high of 56.50. The Drug Manufacturers industry median 3-Year FCF Growth Rate is 8.95. PharmaCielo's value of 29.70% is 231.8% above this industry median. Based on the distribution chart, PharmaCielo ranks #184 out of 660 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does PharmaCielo's 3-Year FCF Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #184 out of 660 companies for 3-Year FCF Growth Rate. This puts PharmaCielo in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 8.95. PharmaCielo's value of 29.70% is 231.8% above this benchmark. Historically, PharmaCielo's own 3-Year FCF Growth Rate has ranged from 29.70 to 56.50 over the past decade. While the company's 10-year median is 43.10 vs. the industry median of 8.95, PharmaCielo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 8.95, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current 3-Year FCF Growth Rate of 29.70% is 231.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for PharmaCielo and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 8.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current 3-Year FCF Growth Rate is 29.70%, which is 31% below median its own 10-year median of 43.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.07, compared to a current price of $0.04 — trading 40.7% below its estimated fair value. The current 3-Year FCF Growth Rate is 29.70%, which is 31% below median its 10-year median of 43.10 and 231.8% above the Drug Manufacturers industry median of 8.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current 3-Year FCF Growth Rate is 29.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your 
